Patent application number | Description | Published |
20080275732 | Using patterns of medical treatment codes to determine when further medical expertise is called for - A technique for using ICD-9 and CPT codes in an individual's medical records to determine a particular manner in which a medical condition of an individual should be dealt with. The medical records are analyzed for a pattern of the medical treatment codes that is associated with the particular manner of dealing with the medical condition and an indication of the pattern's existence is provided. In one embodiment, the analysis is used to determine whether and what kind of specialist is required. The analysis may be performed when the diagnosis of the condition is uncertain, when the treatment of the condition is uncertain, when the treatment has resulted in further problems, or when the patient is not responding to the treatment. | 11-06-2008 |
20090299058 | 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION - Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described. | 12-03-2009 |
20100249201 | 3-3-Di-Substituted-Oxindoles As Inhibitors of Translation Initiation - Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described. | 09-30-2010 |
20100287000 | MEDICAL CONSULTATION MANAGEMENT SYSTEM - A medical consultation support system in which a client computer, such as a personal computer or a terminal of an existing medical support system, is employed to transfer a structured request for consultation from a primary care physician to a supervisory host computer. The structured request may be accompanied by additional information related to the request, such as existing data files containing patient history information, medical image data, laboratory results, pathologies, etc., forming a transmittable, machine-readable collection of information relating to the consultation request. At the supervisory computer, the request is displayed for preliminary review by a receiving staff physician who designates a specialist and retrieves and assembles selected tutorial and background information, including related published articles, tutorial background lessons, practice and protocol documentation, and records of prior consultations which are related to the current consultation request, all of which are stored in one or more databases of medical information accessible to the supervisory host computer. The supervisory computer then transmits the request for consultation, together with at least the identification of the assembled supporting documentation, to the selected specialist for review, and thereafter receives the responsive comment from the selected specialist. The supervisory computer further stores the request for consultation, including the specialist's responsive comment and an identification of the cited supporting material, as a structured case history item in the database of medical information where it may be accessed for future reference. Each consultation is further stored as a recorded learning event associated with the requesting primary care physician, and used to generate a report of continuing legal education credits earned by the requesting physician while participating in the managed consultation sessions. | 11-11-2010 |
20100291024 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE AND PATHOGENIC DISEASES - The invention features peptide fragments containing domain 4 of the | 11-18-2010 |
20110010190 | HEALTH CARE MANAGEMENT SYSTEM - The present invention relates to a system and method for facilitating and managing health care between a medical provider and a patient. In one aspect, the system and method includes providing a patient having a first criteria, which includes a medical symptom. The system and method also include selecting a subset of medical providers having expertise in treating the medical symptom, generating a care request to obtain a treatment proposal for the medical symptom of the patient, and updating the care request with medical information associated with the medical sympton. The system and method further include receiving at least one treatment proposal of the medical symptom from the medical providers and selecting a treatment proposal of the medical symptom from the medical providers. | 01-13-2011 |
20110046367 | 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION - Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described. | 02-24-2011 |
20120135412 | QUALITY CONTROL BIOASSAYS FOR NUTRICEUTICAL AND MEDICINAL PRODUCTS - Bioassays for detecting the ability of one sample of a food substance, nutritional supplement, therapeutic agent and/or disease preventive agent relative to that of a second sample of such a substance, supplement and/or agent to inhibit, upregulate or otherwise modulate translation initiation, and thereby demonstrate a disease curative and/or preventive effect in a human and/or animal that consumes a such substance, supplement and/or agent or to whom a such substance, supplement and/or agent is administered are provided. | 05-31-2012 |
20130178505 | Compounds for the Inhibition of Cellular Proliferation - Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein. | 07-11-2013 |
20130189711 | METHODS, PRODUCTS AND TREATMENTS FOR DIABETES - The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided. | 07-25-2013 |
20130224211 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF - The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the generation of antibodies and antibody fragments. Still other aspects of the invention include methodologies for the preparation of glycated Amadori products of CD59, fragments thereof, the inventive antibodies, and antibody fragments. | 08-29-2013 |
20140322723 | DIABETES DIAGNOSIS THROUGH THE DETECTION OF GLYCATED PROTEINS IN URINE - The invention involves methods, compositions, and kits for detecting glycated proteins in a sample (e.g., urine or other bodily fluid) from a subject. Also provided are methods, compositions, and kits for diagnosing or following a diabetic condition of the subject or screening for a diabetic condition in a population of subjects based upon the detection of the glycated protein(s) in the sample. | 10-30-2014 |